• Explore /
  • Poster
  • / Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC).

Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC).

Abstract Poster

Authors

null

Ryan Sugarman

Memorial Sloan Kettering Cancer Center, New York, NY

Ryan Sugarman , Sasikiran Nunna , Keith A. Betts , Xiaoyu Nie , Hiep Nguyen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02872116

DOI

10.1200/JCO.2022.40.4_suppl.307

Abstract #

307

Poster Bd #

F9

Abstract Disclosures

Similar Posters

First Author: Lin Shen

First Author: Lin Shen

First Author: Kohei Shitara

First Author: Yelena Y. Janjigian